Keywords: urch, study, foresees, pharma, mega-mergers, pfizer, merger
URCH study foresees more pharma mega-mergers
Article | 27 April 2009
Pfizer's merger with fellow US drug major Wyeth (Marketletters pasim) will bring significant change to the pharmaceutical industry and may result in more large deals before the end of the year, suggests a new report. "Mergers and Acquisitions in the Pharmaceuticals Sector, 2009 - Critical success factors for competing in a consolidating market" from URCH Publishing, states that a number of major pharmaceutical players will follow in the footsteps of Pfizer and enter into significant M&A transactions.
"2009 is set to redefine the structure and dynamics of the pharmaceutical industry in a way not seen since the year 2000," says Steve Seget, the report's author. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
